Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chron...

Descripción completa

Detalles Bibliográficos
Autores principales: Cattaneo, C., Cancelli, V., Imberti, L., Dobbs, K., Sottini, A., Pagani, C., Belotti, A., Re, A., Anastasia, A., Quaresima, V., Tucci, A., Chiorini, J. A., Su, H. C., Cohen, J. I., Burbelo, P. D., Rossi, G., Notarangelo, L. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438656/
https://www.ncbi.nlm.nih.gov/pubmed/34521813
http://dx.doi.org/10.1038/s41408-021-00546-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438656/
https://www.ncbi.nlm.nih.gov/pubmed/34521813
http://dx.doi.org/10.1038/s41408-021-00546-9

Ejemplares similares